Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade

Ocular takes another swing at resolving the manufacturing issues that resulted in a complete response letter for its Dextenza.

Blue eye detail

Now that Ocular Therapeutix Inc. has whiffed with a steel blade quick-fix to a particulates issue that delayed approval of its Dextenza (dexamethasone intracanalicular insert), the firm has a new CEO and a more measured plan for getting back into FDA's good graces.

Ocular's final closeout response to pre-approval inspection Form 483 findings, announced July 10, arrived at FDA too late to dissuade the agency from

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Compliance